SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Mumtaz Mahal Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMumtaz Mahal
Date of birth1593-04-27
IdentifiersMRN HR-RE006-SYN-TD; SSN (made up) 000-06-7184
Document date2026-11-01
AuthorFarzana Qureshi-Lindholm, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

First prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk plan. Concerns: Pregnant again soon after her last baby; tired and breathless on stairs, and unsure how far along she is; She has lost six children and wants to do everything possible for this baby and to be well enough for the children she has; Her family may travel again during the pregnancy and she wants to know when and how she can travel safely. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1631-01-06activeS
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other dayOne tablet every other morning with water or orange juice, apart from tea and calciumOral route1631-01-06 to 1631-02-03completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route1631-01-06activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 daysOne capsule twice daily with food for 5 daysOral route1631-03-24 to 1631-03-29completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses)Single infusion; two doses in total, four weeks apartIntravenous route1631-02-03 to 1631-02-03completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses)Single infusion; two doses in total, four weeks apartIntravenous route1631-03-03 to 1631-03-03completedS

Procedures

ProcedureDatesStatusEvidence
First-trimester ultrasound for dating and nuchal translucency: single live intrauterine fetus, crown-rump length 72 mm (13 weeks 2 days), nuchal translucency 1.7 mm, nasal bone present; placenta posterior; no structural abnormality seen1631-01-06 to 1631-01-06completedS
Detailed fetal anatomy ultrasound at 21 weeks 2 days: single fetus, normal anatomy, estimated weight 410 g; placenta posterior and fundal, lower edge more than 5 cm from the internal os; no placental lacunae, normal retroplacental clear zone and myometrial thickness; normal amniotic fluid1631-03-03 to 1631-03-03completedS
Third-trimester growth ultrasound at 34 weeks 2 days: cephalic presentation, estimated weight 2380 g (about the 45th centile), normal amniotic fluid, placenta posterior fundal1631-06-02 to 1631-06-02completedS

Immunizations

DateVaccineStatusEvidence
1631-01-06Influenza vaccine, 1630-1631 season, given in pregnancycompletedS
1631-04-14Tdap vaccine in pregnancy, 27 weekscompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1613 to 1630Thirteen births between 1613 and 1630, the last in April 1630, while travelling with the courtD (CLM-0006, CLM-0005)

Family History

RelativeConditionAge at deathEvidence
natural daughterEldest daughter died of smallpox in 1616, aged three3D (CLM-0007)
natural sonA son died in infancy in 1621; cause not recorded in the cited sourceD (CLM-0007)
natural sonA son died soon after birth in 1622; cause not recorded in the cited sourceD (CLM-0007)
natural daughterA daughter died of smallpox in 1628, aged seven7D (CLM-0007)
natural sonA son died in 1628 at about eighteen months; cause not recorded in the cited sourceD (CLM-0007)
natural sonA son died in infancy in 1629; cause not recorded in the cited sourceD (CLM-0007)

Health Concerns

ConcernStatusEvidence
Pregnant again soon after her last baby; tired and breathless on stairs, and unsure how far along she isactiveS
She has lost six children and wants to do everything possible for this baby and to be well enough for the children she hasactiveS
Her family may travel again during the pregnancy and she wants to know when and how she can travel safelyactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 11.8 on 1631-06-02; MCV [Entitic mean volume] in Red Blood Cells by Automated count 76 on 1631-01-06; Leukocytes [#/volume] in Blood by Automated count 8.6 on 1631-01-06; Platelets [#/volume] in Blood by Automated count 228 on 1631-06-02; Ferritin [Mass/volume] in Serum or Plasma 110 on 1631-04-14; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 1631-01-06; Fetal Crown Rump length US 72 on 1631-01-06; Fetal nuchal translucency measured by US 1.7 on 1631-01-06; Total score [EPDS] 5 on 1631-06-02; Fetal Body weight estimated by US 2380 on 1631-06-02; Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO 128 on 1631-04-14 [S]

Strengths and supports: Supports: a large household, her eldest daughter, and a close woman friend who travels with her [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12activeconfirmed O09.529S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic.
Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living childrenactiveconfirmed O09.40S — Synthetic modern problem anchored to her documented thirteen earlier births.
Short interpregnancy interval: conception about five and a half months after her last birthactiveconfirmed O09.899S — Synthetic modern problem anchored to the documented fourteen months between her last two births.
Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mLactiveconfirmed O99.019S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis.
Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolvedresolvedconfirmed O23.12S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1631-01-06Hemoglobin [Mass/volume] in Blood10.1g/dL11-15 g/dLLowS
1631-01-06MCV [Entitic mean volume] in Red Blood Cells by Automated count76fL80-100 fLLowS
1631-01-06Leukocytes [#/volume] in Blood by Automated count8.610*3/uL4-13 10*3/uLNormalS
1631-01-06Platelets [#/volume] in Blood by Automated count24510*3/uL150-400 10*3/uLNormalS
1631-01-06Ferritin [Mass/volume] in Serum or Plasma9ng/mL30-150 ng/mLLowS
1631-01-06Hemoglobin A1c/Hemoglobin.total in Blood5.4%<=5.7%NormalS
1631-01-06Fetal Crown Rump length US72mmConsistent with 13 weeks 2 days; used for dating because her last period is not knownNormalS
1631-01-06Fetal nuchal translucency measured by US1.7mm<=3.5 mmNormalS
1631-01-06Total score [EPDS]8{score}S
1631-02-03Hemoglobin [Mass/volume] in Blood10.3g/dL10.5-15 g/dLLowS
1631-02-03Ferritin [Mass/volume] in Serum or Plasma12ng/mL30-150 ng/mLLowS
1631-03-03Hemoglobin [Mass/volume] in Blood10.9g/dL10.5-15 g/dLNormalS
1631-03-03Ferritin [Mass/volume] in Serum or Plasma96ng/mL30-150 ng/mLNormalS
1631-03-03Fetal Body weight estimated by US410gAbout the 50th centile for 21 weeksNormalS
1631-04-14Hemoglobin [Mass/volume] in Blood11.4g/dL10.5-15 g/dLNormalS
1631-04-14Ferritin [Mass/volume] in Serum or Plasma110ng/mL30-150 ng/mLNormalS
1631-04-14Platelets [#/volume] in Blood by Automated count23210*3/uL150-400 10*3/uLNormalS
1631-04-14Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO128mg/dL<=139 mg/dLNormalS
1631-04-14Total score [EPDS]6{score}S
1631-06-02Hemoglobin [Mass/volume] in Blood11.8g/dL11-15 g/dLNormalS
1631-06-02Platelets [#/volume] in Blood by Automated count22810*3/uL150-400 10*3/uLNormalS
1631-06-02Total score [EPDS]5{score}S
1631-06-02Fetal Body weight estimated by US2380gAbout the 45th centile for 34 weeksNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1631-01-06Body height157cmS
1631-01-06Body weight58.6kgS
1631-01-06Body mass index (BMI) [Ratio]23.8kg/m2S
1631-01-06Systolic blood pressure104mm[Hg]S
1631-01-06Diastolic blood pressure64mm[Hg]S
1631-01-06Heart rate84/minS
1631-01-06Respiratory rate14/minS
1631-01-06Body temperature36.7CelS
1631-01-06Oxygen saturation in Arterial blood by Pulse oximetry99%S
1631-02-03Body height157cmS
1631-02-03Body weight59.8kgS
1631-02-03Body mass index (BMI) [Ratio]24.3kg/m2S
1631-02-03Systolic blood pressure106mm[Hg]S
1631-02-03Diastolic blood pressure64mm[Hg]S
1631-02-03Heart rate86/minS
1631-02-03Respiratory rate14/minS
1631-02-03Body temperature36.6CelS
1631-02-03Oxygen saturation in Arterial blood by Pulse oximetry99%S
1631-03-03Body height157cmS
1631-03-03Body weight61.9kgS
1631-03-03Body mass index (BMI) [Ratio]25.1kg/m2S
1631-03-03Systolic blood pressure104mm[Hg]S
1631-03-03Diastolic blood pressure62mm[Hg]S
1631-03-03Heart rate88/minS
1631-03-03Respiratory rate14/minS
1631-03-03Body temperature36.7CelS
1631-03-03Oxygen saturation in Arterial blood by Pulse oximetry99%S
1631-03-24Body height157cmS
1631-03-24Body weight62.6kgS
1631-03-24Body mass index (BMI) [Ratio]25.4kg/m2S
1631-03-24Systolic blood pressure108mm[Hg]S
1631-03-24Diastolic blood pressure66mm[Hg]S
1631-03-24Heart rate92/minS
1631-03-24Respiratory rate16/minS
1631-03-24Body temperature37.1CelS
1631-03-24Oxygen saturation in Arterial blood by Pulse oximetry99%S
1631-04-14Body height157cmS
1631-04-14Body weight64.6kgS
1631-04-14Body mass index (BMI) [Ratio]26.2kg/m2S
1631-04-14Systolic blood pressure108mm[Hg]S
1631-04-14Diastolic blood pressure68mm[Hg]S
1631-04-14Heart rate86/minS
1631-04-14Respiratory rate16/minS
1631-04-14Body temperature36.7CelS
1631-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S
1631-06-02Body height157cmS
1631-06-02Body weight68kgS
1631-06-02Body mass index (BMI) [Ratio]27.6kg/m2S
1631-06-02Systolic blood pressure112mm[Hg]S
1631-06-02Diastolic blood pressure70mm[Hg]S
1631-06-02Heart rate88/minS
1631-06-02Respiratory rate16/minS
1631-06-02Body temperature36.8CelS
1631-06-02Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1631-01-06First prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk planfinishedS
1631-02-03Prenatal visit at 17 weeks, with maternal-fetal medicine consultationfinishedS
1631-03-03Prenatal visit at 21 weeks with the anatomy scan and placental locationfinishedS
1631-04-14Prenatal visit at 27 weeks: glucose challenge, blood count, and TdapfinishedS
1631-06-02Prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counselingfinishedS
1631-03-24Same-day sick visit for painful, frequent urination at 24 weeksfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
First prenatal visit: dating and nuchal translucency scan; blood count, ferritin, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture for asymptomatic bacteriuria; hemoglobin electrophoresis for microcytosis; hemoglobin A1c as an early diabetes screen; influenza vaccine; folic acidcompletedGL-USPSTF-AB, GL-CDC-PREGVAX, GL-ACOG-AMA-2022S
Aneuploidy screening offered, with diagnostic testing available: cell-free DNA and the nuchal translucency measurement today, or chorionic villus sampling or amniocentesis; she chose cell-free DNAcompletedGL-ACOG-ANEU-2020, GL-ACOG-AMA-2022S
Maternal-fetal medicine consultation for a fourteenth pregnancy at 37 with a short interpregnancy interval and anemia: surveillance, anemia treatment, placental assessment, delivery timing and place, and postpartum hemorrhage planningcompletedGL-ACOG-AMA-2022, GL-ACOG-PPH-2017S
Iron deficiency anemia: ferrous sulfate 325 mg every other day; repeat blood count and ferritin in four weeks, with intravenous iron in the second trimester if she cannot tolerate oral iron or the hemoglobin does not rise; aim for hemoglobin of 11 g/dL or more before deliverycompletedGL-ACOG-ANEMIA-2021S
Preeclampsia prevention: aspirin 81 mg at bedtime from 13 weeks until delivery for two moderate risk factors (age 35 or older and a previous adverse pregnancy outcome); blood pressure and urine protein at every visitcompletedGL-USPSTF-ASA-2021S
Detailed anatomy scan at 20 to 22 weeks with placental location; if the placenta is low-lying or covers the cervix, a repeat scan at 32 weeks and assessment for placenta accreta spectrumcompletedGL-ACOG-AMA-2022, GL-ACOG-PAS-2018S
Gestational diabetes: hemoglobin A1c today because she is of South Asian heritage with a BMI of 23 or more; one-hour glucose challenge at 24 to 28 weekscompletedGL-ACOG-GDM-2018S
Travel: travel is reasonable until about 36 weeks if the pregnancy stays uncomplicated; on long journeys walk every one to two hours, drink plenty, and wear compression stockings; carry her prenatal record; find maternity care where she stays; stay near the delivery hospital from 36 weekscompletedGL-ACOG-TRAVEL-2018S
Postpartum hemorrhage risk assessment at intake and again in the third trimester and on admission for birth (grand multiparity and anemia raise her risk); delivery planned in a hospital with a blood bank, anesthesia, and an operating theatrecompletedGL-ACOG-PPH-2017, GL-WHO-PPH-2012S
Mood: EPDS in each trimester, with support for the grief of having lost several childrencompletedGL-ACOG-MH-2023S
Postpartum hemorrhage plan for birth: induction at 39 weeks in hospital; type and screen and blood count on admission; two large-bore intravenous lines; avoid prolonged labor, with timely assessment of progress; oxytocin 10 units after birth as active management of the third stage; quantitative blood loss; tranexamic acid 1 g intravenously within 3 hours of birth if hemorrhage is diagnosed, with a second 1 g dose if bleeding continues after 30 minutes; second-line uterotonics, a uterine balloon, and the massive transfusion protocol readycompletedGL-ACOG-PPH-2017, GL-WHO-PPH-2012, GL-WHO-TXA-2017, GL-WOMAN-2017, GL-ACOG-AMA-2022S
Contraception and interpregnancy interval, on her own terms: options explained (implant, hormonal or copper IUD, progestin-only pill, lactational amenorrhea, and permanent methods); she chose an etonogestrel implant before discharge after the birth and plans to wait at least 18 to 24 months before any future pregnancycompletedGL-ACOG-IPC-2019, GL-CDC-USMEC-2024S

Goals

GoalTargetStatusOutcomeProvenance
Hemoglobin at least 11 g/dL with replete iron stores before delivery1631-06-02completedHemoglobin 11.8 g/dL and ferritin 110 ng/mL after two doses of intravenous ironS
An informed choice about aneuploidy screening by 14 weeks1631-02-03completedChose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testingS
Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks1631-07-12activeBlood pressure 104/62 to 112/70 mmHg throughout; aspirin taken nightlyS
A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre1631-06-02completedPlan agreed at 34 weeks: induction at 39 weeks at the hospital, oxytocin after birth, quantitative blood loss, and tranexamic acid readyS
A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery1631-06-02completedChose an etonogestrel implant before discharge after the birth; plans at least 18 to 24 months before any future pregnancyS

Functional Status

Mental Status